Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by jimmyhorizonon Nov 23, 2021 5:35am
360 Views
Post# 34155803

Questions for the next quarterly update

Questions for the next quarterly update
On April 1, 2021, management published an investor presentation and stated, among other things, the following milestones to be achieved by the end of May:

Finalize due diligence and agree on terms with new organization
Finalize Tinyi agreement


What led management to believe that negotiations with a Chinese company for the development of TFC 1067 would be completed by the end of May?
What are the results of the due diligence?
What is the status of the negotiations with the Chinese company?
Why has the Tinyi agreement not yet been finalized?
What is the status of negotiations with Tinyi?

In the current investor presentation it now says
Establish terms with new organization in China for TFC-1067
Why was this changed?
Why is it now called establish and not finalize?
How can this be 6 months after  end of May?

Completed an additional licensing agreement for the SGLT2 inhibitor in new markets

This agreement was already announced for Christmas 2020. How did this happen? Why did management assume that a contract could be signed by Christmas 2020?
In the meantime, we have been informed that there are problems with production. Has the project failed?
What is the status of negotiations with the 2 or now 4 global partners?

Secure non-dilutive funding through anticipated collaborations

Does this mean that warrant holders are being persuaded to exercise their warrants shortly before they expire by fabricated stories?

Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II

Why have the results not yet been announced?
If Phase I had been successfully completed, would the results have been announced?
Why is Wanbang withholding the results? Are they allowed to do that?
If the results have not been announced after half a year, it can only mean that Phase I has failed. Wouldn't that be material information that should be published?     

The following milestone was marked as complete
Begin large-scale manufacturing of TFC-1067 at a major manufacturer     
What does large scale mean?
Who is the major manufacturer?
For whom is large scale produced?
Are there large scale sales in addition to the large scale production?
Shouldn't sales figures be published in the interim financial statements?
If so, why is the public kept in the dark about future sales figures?
What is management's view of future sales of TFC 1067 to R&F?

Does management believe there is no legitimate interest in any of the above questions? if so, which of the questions?

What effect does management think it has on credibility when it keeps coming up with new stories and promises and, after a lapse of time, leaves even the questions it raises simply unanswered?

Management posted a rocket 6 weeks ago on twitter announcing a strong newsflow.
What does strong newsflow mean?
Does flow indicate an increase in the number of news items?
Why was the rocket posted 6 weeks ago? Did it have something to do with the expiration of the warrants?

Management said an extensive du diligence was completed with a top10 pharma company. 6 weeks later it says there is further due diligence. Is this an indication that negotiations are delayed or have failed?









<< Previous
Bullboard Posts
Next >>